Latest news with #patientfootfall
Khaleej Times
5 days ago
- Business
- Khaleej Times
Burjeel net profit surges 128.9% in the second quarter
Burjeel Holdings delivered strong top-line growth of 18.7 per cent to Dh1,403 million in Q2'25, driven by a 12.1 per cent increase in patient footfall, higher patient yield, and the continued ramp-up of newly launched facilities across the network, the super-specialty healthcare services provider announced on Thursday. Net profit surged 128.9 per cent to Dh148 million in Q2'25, reflecting margin expansion, enhanced operating leverage, and asset optimisation. In H1'25, net profit rose 10.6 per cent to Dh187 million. Ebitda rose 59.4 per cent to Dh306 million in Q2'25, fuelled by strong revenue growth, enhanced physician productivity, and better performance across recently ramped-up assets. This includes Dh72 million in gains from lease liability derecognition following the Dubai Medeor Hospital acquisition. The Ebitda margin expanded 5.6 p.p. to 21.8 per cent. In H1'25, Ebitda increased 14.2 per cent to Dh487 million, with a margin of 18.2 per cent. Revenue in H1'25 rose 12.2 per cent to Dh2,677 million, with total patient visits reaching 3.4 million. Oncology remained a core growth driver, with revenue rising 36.7 per cent in Q2'25 and 38.1 per cent in H1'25, underpinned by oncology network expansion and improved conversion in surgical and advanced therapies. Other specialties also recorded solid gains in H1'25, including urology (+18 per cent), emergency medicine (+17 per cent), cardiology (+16 per cent), and gastroenterology (+13 per cent). John Sunil, CEO of Burjeel Holdings, was optimistic about maintaining strong momentum through the second half. 'We continue to target mid-teens revenue growth for the year, supported by the ramp-up of new assets and strategic expansion in both the UAE and Saudi Arabia,' he said. A key focus is making sure that Burjeel's new centres and services are launched smoothly and begin contributing at full potential. 'Major investments in specialised care, technology, and new geographies do not translate into financial returns overnight. But the strategy we have been executing is absolutely the right one, and this quarter's results are a clear example of how our growth strategy and investments in complex care are beginning to yield measurable financial results,' Sunil said. Inpatient footfall rose 17.7 per cent in Q2'25, reflecting strong demand across key specialties and a ramp-up in elective surgeries post-Ramadan. Outpatient footfall grew 12.0 per cent in Q2'25, accelerating from 5.2 per cent in Q1, driven by primary care and physiotherapy centers, along with robust demand in oncology, pediatrics, ophthalmology, and family medicine. Utilisation improved to 68 per cent, up from 65 per cent in Q1'25, enabled by optimised hiring and scaling of clinical teams. The Hospitals segment continued to drive group performance, contributing 89 per cent of total revenue in Q2'25. Revenue grew 17.3 per cent to Dh1,245 million, supported by strong growth in patient volumes and sustained demand for complex care services. Segment Ebitda rose by 40.6 per cent, led by strong performance across key hospitals. Operating cash flow increased 8.1 per cent YoY in H1'25, driven by improved operational performance and disciplined working capital management. Maintenance capex remained in line with guidance, while growth capex totalled Dh403 million, driven by strategic M&A activities and ongoing network expansion. Free cash flow conversion improved to 54 per cent in H1'25. In May 2025, the Group declared a full-year dividend of Dh170 million for FY2024, representing 47 per cent of net profit. Cost control was a key contributor to the company's performance. 'Even with 143 new physicians onboarded over the past year, we were able to optimise personnel costs through better workforce planning and clinical scheduling. We also brought overheads down by 7 per cent quarter-on-quarter and over 13 per cent compared to Q4, by normalising spend and embedding stronger cost discipline across the group. These efforts, alongside strong top-line growth, drove a significant improvement in margins,' Sunil said. The Trust Fertility Center, now the largest in the UAE, broke even within six months and has served over 1,800 unique patients with outcomes well above global benchmarks. 'It plays a key role in our women's health platform and aligns with the UAE's national fertility strategy. Looking ahead, we're replicating this model in Al Ain and Dubai, while continuing to invest in precision medicine, AI-enabled care, and complex specialties,' Sunil said.
Zawya
5 days ago
- Business
- Zawya
Burjeel reports 129% increase in Q2 net profit, revenue grows 18.7%
UAE - Burjeel Holdings, a leading super-specialty healthcare services provider in MENA, has delivered a strong top-line growth of 18.7% to AED1,403 million ($381.98 million) in Q2 2025, driven by a 12.1% increase in patient footfall, higher patient yield, and the continued ramp-up of newly launched facilities across the network. Revenue in H1'25 rose 12.2% to AED2,677 million, with total patient visits reaching 3.4 million, the healthcare provider said. EBITDA rose 59.4% to AED306 million in Q2 2025, fueled by strong revenue growth, enhanced physician productivity, and better performance across recently ramped-up assets. This includes AED72 million in gains from lease liability derecognition following the Dubai Medeor Hospital acquisition. The EBITDA margin expanded 5.6 p.p. to 21.8%. In H1'25, EBITDA increased 14.2% to AED487 million, with a margin of 18.2%. Net profit surged 128.9% to AED148 million ($40.29 million) in Q2' 2025, reflecting margin expansion, enhanced operating leverage, and asset optimization. In H1'25, net profit rose 10.6% to AED187 million. Specialised Services, expansion Burjeel Holdings accelerated its strategic execution in Q2 2025 with a series of high-impact initiatives that deepened specialisation and broadened patient access. The group expanded its advanced oncology network, integrating Dubai's Advanced Care Oncology Center and opening new Burjeel Cancer Institute (BCI) clinics in Al Ain, Sharjah, and Oman, reinforcing its position as a regional leader in complex cancer care. The UAE's first dedicated cancer pharmacy was also inaugurated, strengthening oncology support infrastructure. In parallel, Burjeel launched a regional mental health platform through its joint venture Alkalma, opening four specialist mental health centers across the UAE and Saudi Arabia. This marked the first phase of a multi-year expansion strategy aimed at addressing rising demand for mental wellness services. In Saudi Arabia, the Group acquired a major physiotherapy facility in Riyadh under the PhysioTherabia platform, adding scale and unlocking turnaround potential through secured government contracts. Investments in operational resilience and access continued with the AED170 million acquisition of the Medeor Hospital Dubai building, converting long-term lease obligations into ownership and enhancing cost structure flexibility. The group also expanded its primary care footprint with a new medical center launched on Saadiyat Island, aligning with its growth strategy in high-yield urban catchments. In medical innovation, Burjeel launched Docktour, a transformative healthcare logistics joint venture with AD Ports Group, aiming to redefine how medical services and infrastructure are delivered to underserved and remote communities. Several specialised centers were introduced, including the region's first Al Muderis Osseointegration Clinic for advanced limb reconstruction, a state-of-the-art Epilepsy Monitoring Unit, and expanded capabilities in rare diseases, hematology, and metabolic research. Additionally, the Group continued its digital transformation with AI-powered diagnostics and led groundbreaking research in microgravity, aiming to transform care for patients with diabetes in space and on Earth. John Sunil, Chief Executive Officer of Burjeel Holdings, said: 'The second quarter delivered exceptionally strong results, with 19% revenue growth driven by a 12% increase in patient footfall and improved yield. EBITDA rose by 59%, accompanied by a margin uplift to 22%. This robust performance significantly strengthened the first-half outcome, underscoring Burjeel Holdings' resilience and long-term sustainable growth. 'These results reflect tangible progress in key operational areas such as physician manpower optimization, formulary management, and cost control, while our strategic focus on super-specialty care is beginning to yield measurable benefits, enhancing both revenue and profitability. We continue to invest in high-value services and next-generation care facilities to support long-term momentum. 'We also advanced key strategic priorities, reinforcing leadership in complex care across oncology, transplants, fertility, mental health, and diagnostics. Our oncology platform is now the UAE's largest private network, featuring new cancer clinics and cell and gene therapy capabilities. The Alkalma mental health platform is scaling regionally, alongside rehabilitation services through over 30 PhysioTherabia centers in Saudi Arabia. Additionally, we introduced the region's first Osseointegration Clinic for cutting-edge prosthetic care. 'In parallel with expanding our network of primary care and medical centers, we deepened partnerships with government and corporate stakeholders and accelerated digital integration through Oracle Health EMR and AI-powered tools. Building on this platform, we entered into pivotal partnerships in oncology, value-based care, diagnostics, and international healthcare innovation, establishing the Group as the healthcare partner of choice. 'Burjeel Holdings is uniquely positioned to capture significant opportunities across the region, supported by rising demand for complex care and a growing population. Our focus remains on converting recent investments into sustained expansion and margin improvement, while maintaining disciplined financial management to support long-term shareholder value. Net profit growth of 129% in the reporting quarter reinforces this trajectory and strengthens the foundation for consistent shareholder returns.' Growth drivers Oncology remained a core growth driver, with revenue rising 36.7% in Q2'25 and 38.1% in H1'25, underpinned by oncology network expansion and improved conversion in surgical and advanced therapies. Other specialties also recorded solid gains in H1'25, including urology (+18%), emergency medicine (+17%), cardiology (+16%), and gastroenterology (+13%). Inpatient footfall rose 17.7% in Q2'25, reflecting strong demand across key specialties and a ramp-up in elective surgeries post-Ramadan. The group performed 22,930 surgeries, up 18.7%, with momentum concentrated at Burjeel Medical City, Burjeel Specialty Hospital Sharjah, Lifecare Hospital Musaffah and Burjeel Royal Hospital Al Ain. Bed occupancy improved to 69%, up from 65% a year ago, and averaged 69% in H1'25. Inpatient volumes rose 14.6% over the first half. Outpatient footfall grew 12.0% in Q2'25, accelerating from 5.2% in Q1, driven by primary care and physiotherapy centers, along with robust demand in oncology, pediatrics, ophthalmology, and family medicine. Utilization improved to 68%, up from 65% in Q1'25, enabled by optimized hiring and scaling of clinical teams. Leading facilities included Burjeel Medical City, Lifecare Hospital Baniyas, and Burjeel Day Surgery Center Barari. In H1'25, outpatient volumes increased 8.6%.
